Viewing Study NCT00003737



Ignite Creation Date: 2024-05-05 @ 11:08 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00003737
Status: COMPLETED
Last Update Posted: 2013-06-25
First Post: 1999-11-01

Brief Title: Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: Memorial Sloan Kettering Cancer Center

Study Overview

Official Title: A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC 655649 in Pediatric Patients With RelapsedRefractory Neuroblastoma
Status: COMPLETED
Status Verified Date: 2013-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma
Detailed Description: OBJECTIVES

Determine the response rate to rebeccamycin analogue in children with relapsed or refractory neuroblastoma
Determine the toxicity of this drug in these patients
Identify and establish in vitro biologic correlates of clinical responses and toxicity of this drug in these patients

OUTLINE Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5 Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity

PROJECTED ACCRUAL This study will accrue up to 30 patients within 15 years

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
NCI-T98-0041 Registry Identifier PDQ Physician Data Query None
CDR0000066852 REGISTRY None None